Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bruton's Tyrosine Kinase”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT03571308
What this trial is testing

A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)

Who this might be right for
Non Hodgkin Lymphoma
University Hospital Southampton NHS Foundation Trust 39
Early research (Phase 1)Study completedNCT02211014
What this trial is testing

An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM)
Acerta Pharma BV 27
Testing effectiveness (Phase 2)WithdrawnNCT03370185
What this trial is testing

Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

Who this might be right for
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
SecuraBio
Testing effectiveness (Phase 2)Ended earlyNCT02943473
What this trial is testing

Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients

Who this might be right for
High Risk Smoldering Multiple Myeloma
Icahn School of Medicine at Mount Sinai 9
Early research (Phase 1)Ended earlyNCT03671590
What this trial is testing

Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies

Who this might be right for
Non Hodgkin LymphomaChronic Lymphocytic Leukemia
TG Therapeutics, Inc. 172
Testing effectiveness (Phase 2)Ended earlyNCT02975349
What this trial is testing

Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis

Who this might be right for
Relapsing-remitting Multiple Sclerosis
EMD Serono Research & Development Institute, Inc. 267
Early research (Phase 1)Study completedNCT07214935
What this trial is testing

A TQT Study of Effect of M2951 on Cardiac Repolarization

Who this might be right for
Healthy
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany 36
Testing effectiveness (Phase 2)Looking for participantsNCT06520098
What this trial is testing

Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Who this might be right for
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
VA Office of Research and Development 100
Large-scale testing (Phase 3)Study completedNCT01646021
What this trial is testing

Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

Who this might be right for
Mantle Cell Lymphoma
Janssen Research & Development, LLC 280
Early research (Phase 1)Study completedNCT02829541
What this trial is testing

A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), and Pharmacodynamic(PD) Study of BIIB068 in Healthy Participants

Who this might be right for
Systemic Lupos Erythematosus, SLE
Biogen 36
Large-scale testing (Phase 3)Active Not RecruitingNCT06840392
What this trial is testing

Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

Who this might be right for
Hidradenitis Suppurativa
Novartis Pharmaceuticals 565
Early research (Phase 1)Study completedNCT01704963
What this trial is testing

Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms

Who this might be right for
Recurrent Mature B-cell Neoplasms
Janssen Pharmaceutical K.K. 15
Testing effectiveness (Phase 2)UnknownNCT02747732
What this trial is testing

Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL

Who this might be right for
Diffuse Large B Cell LymphomaPrimary Mediastinal (Thymic) Large B-cell LymphomaTransformed Indolent Lymphoma+2 more
Meirav Kedmi MD 72
Not applicableActive Not RecruitingNCT04882475
What this trial is testing

Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Who this might be right for
Mantle Cell Lymphoma
Fondazione Italiana Linfomi - ETS 160
Not applicableLooking for participantsNCT06151730
What this trial is testing

Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

Who this might be right for
Chronic Lymphocytic LeukemiaHematopoietic and Lymphoid System NeoplasmMantle Cell Lymphoma+2 more
Mayo Clinic 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT06524375
What this trial is testing

Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period

Who this might be right for
Chronic Lymphocytic Leukemia
Genentech, Inc. 118
Testing effectiveness (Phase 2)Study completedNCT03145064
What this trial is testing

Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma

Who this might be right for
Diffuse Large B-cell Lymphoma
BeiGene 41
Testing effectiveness (Phase 2)Study completedNCT02760485
What this trial is testing

Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Lymphoma
Incyte Corporation 33
Early research (Phase 1)Study completedNCT04436107
What this trial is testing

Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BeiGene 66
Testing effectiveness (Phase 2)Study completedNCT02077166
What this trial is testing

Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Relapsed Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
Pharmacyclics LLC. 138
Next Page